Galcanezumab in episodic migraine: the phase 3, randomized, double-blind, placebo-controlled PERSIST study

被引：0

作者：

Bo Hu

Gang Li

Xiaohong Li

Shan Wu

Tingmin Yu

Xiang Li

Hongru Zhao

Zhihua Jia

Junpeng Zhuang

Shengyuan Yu

机构：

[1] Union Hospital,Department of Neurology

[2] Tongji Medical College,Department of Neurology

[3] Huazhong University of Science and Technology,Department of Neurology

[4] Shanghai East Hospital,Department of Neurology

[5] School of Medicine,Department of Neurology

[6] Tongji University,Department of Neurology

[7] Jinan Central Hospital,Department of Neurology

[8] Cheeloo College of Medicine,Department of Neurology

[9] Shandong University,undefined

[10] Affiliated Hospital of Guizhou Medical University,undefined

[11] The Second Hospital of Jilin University,undefined

[12] Huashan Hospital,undefined

[13] Shanghai Medical College,undefined

[14] Fudan University,undefined

[15] The First Affiliated Hospital of Soochow University,undefined

[16] Chinese PLA General Hospital,undefined

[17] Eli Lilly and Company,undefined

来源：

The Journal of Headache and Pain | 2022年 / 23卷

关键词：

Calcitonin gene-related peptide; Galcanezumab; Humanized monoclonal antibody; Episodic migraine;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[1] Galcanezumab in episodic migraine: the phase 3, randomized, double-blind, placebo-controlled PERSIST study
Hu, Bo
Li, Gang
Li, Xiaohong
Wu, Shan
Yu, Tingmin
Li, Xiang
Zhao, Hongru
Jia, Zhihua
Zhuang, Junpeng
Yu, Shengyuan
[J]. JOURNAL OF HEADACHE AND PAIN, 2022, 23 (01):
[2] A phase 3 placebo-controlled study of galcanezumab in patients with episodic migraine: Results from the 3-month double-blind treatment phase of the PERSIST study
Yu, S.
Hu, B.
Li, G.
Jia, Z.
Chowdhury, D.
Zhuang, J.
Qian, C.
[J]. HEADACHE, 2022, 62 : 130 - 131
[3] Galcanezumab in chronic migraine The randomized, double-blind, placebo-controlled REGAIN study
Detke, Holland C.
Goadsby, Peter J.
Wang, Shufang
Friedman, Deborah I.
Selzler, Katherine J.
Aurora, Sheena K.
[J]. NEUROLOGY, 2018, 91 (24) : E2211 - E2221
[4] 100% RESPONSE RATE TO GALCANEZUMAB IN PATIENTS WITH EPISODIC MIGRAINE: RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES
Nagy, A. J.
Pearlman, E.
Ruff, D.
Day, K.
Aurora, S. K.
Rosen, N.
[J]. CEPHALALGIA, 2018, 38 : 63 - 64
[5] 100% response rate to galcanezumab in patients with episodic migraine: randomized, double-blind, placebo-controlled studies
Nagy, Abraham Jim
Pearlman, Eric
Ruff, Dustin
Day, Kathleen
Rosen, Noah
[J]. JOURNAL OF HEADACHE AND PAIN, 2018, 19
[6] Impact of Galcanezumab on Total Pain Burden: Findings from Phase 3 Randomized, Double-Blind, Placebo-Controlled Studies in Patients with Episodic or Chronic Migraine
Ailani, Jessica
Andrews, J. Scott
Rettiganti, Mallikarjuna
Nicholson, Robert
[J]. NEUROLOGY, 2020, 94 (15)
[7] Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)
Ashina, Messoud
Saper, Joel
Cady, Roger
Schaeffler, Barbara A.
Biondi, David M.
Hirman, Joe
Pederson, Susan
Allan, Brent
Smith, Jeff
[J]. CEPHALALGIA, 2020, 40 (03) : 241 - 254
[8] Measures of Functioning in Patients With Episodic Migraine: Findings From a Double-Blind, Randomized, Placebo-Controlled Phase 2b Trial With Galcanezumab
Ayer, David W.
Skljarevski, Vladimir
Ford, Janet H.
Nyhuis, Allen W.
Lipton, Richard B.
Aurora, Sheena K.
[J]. HEADACHE, 2018, 58 (08): : 1225 - 1235
[9] Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine
Goadsby, Peter J.
Wietecha, Linda A.
Dennehy, Ellen B.
Kuca, Bernice
Case, Michael G.
Aurora, Sheena K.
Gaul, Charly
[J]. BRAIN, 2019, 142 : 1894 - 1904
[10] Post-hoc Outcomes from a Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Patients with Episodic Cluster Headache
Kudrow, D.
Oakes, T. M.
Bardos, J.
Andrews, J.
Rettiganti, M.
Zhou, C.
Riesenberg, R.
Wenzel, R.
Kuruppu, D.
Martinez, J.
[J]. HEADACHE, 2019, 59 : 193 - 193

← 1 2 3 4 5 →